Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options
Cardiovascular Research · 07.08.2023 · 119 (9) · 1787-1798
DOI: 10.1093/cvr/cvad095 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Research, online erschienen am 26.06.2023. Verfasst von Christoph Grander und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Anichstrasse 35, Innsbruck…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Insulin Resistance. Die Arbeit wurde bisher 210-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The prevalence of non-alcoholic fatty liver disease (NAFLD) is continually increasing due to the global obesity epidemic. NAFLD comprises a systemic metabolic disease accompanied frequently by insulin resistance and hepatic and systemic inflammation. Whereas simple hepatic steatosis is the most common disease manifestation, a more progressive disease course characterized by liver fibrosis and inflammation (i.e. non-alcoholic steatohepatitis) is present in 10–20% of affected individuals. NAFLD furthermore progresses in a substantial number of patients towards liver cirrhosis and hepatocellular carcinoma. Whereas this disease now affects almost 25% of the world’s population and is mainly observed in obesity and type 2 diabetes, NAFLD also affects lean individuals. Pathophysiology involves lipotoxicity, hepatic immune disturbances accompanied by hepatic insulin resistance, a gut dysbiosis, and commonly hepatic and systemic insulin resistance defining this disorder a prototypic systemic metabolic disorder. Not surprisingly many affected patients have other disease manifestations, and indeed cardiovascular disease, chronic kidney disease, and extrahepatic malignancies are all contributing substantially to patient outcome. Weight loss and lifestyle change reflect the cornerstone of treatment, and several medical treatment options are currently under investigation. The most promising treatment strategies include glucagon-like peptide 1 receptor antagonists, sodium–glucose transporter 2 inhibitors, Fibroblast Growth Factor analogues, Farnesoid X receptor agonists, and peroxisome proliferator–activated receptor agonists. Here, we review epidemiology, pathophysiology, and therapeutic options for NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Anichstrasse 35, Innsbruck 6020, Austria.
Zitieren
APA
Grander, C., Grabherr, F., & Tilg, H. (2023). Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovascular Research, 119(9), 1787-1798. https://doi.org/10.1093/cvr/cvad095
Vancouver
Grander C, Grabherr F, Tilg H. Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options. Cardiovascular Research. 2023;119(9):1787-1798. doi:10.1093/cvr/cvad095
BibTeX
@article{Grander2023,
author = {Grander, Christoph and Grabherr, Felix and Tilg, Herbert},
title = {Non-alcoholic fatty liver disease: pathophysiological concepts and treatment options},
journal = {Cardiovascular Research},
year = {2023},
volume = {119},
number = {9},
pages = {1787--1798},
doi = {10.1093/cvr/cvad095}
}
EUVIMED